Justificativa e delineamento do estudo Tocilizumabe em pacientes com COVID-19 moderado a grave: estudo aberto, multicêntrico, randomizado, controlado (TOCIBRAS)

Farias, Danielle Leão Cordeiro de; Prats, João; Cavalcanti, Alexandre Biasi; Rosa, Regis Goulart; Machado, Flávia Ribeiro; Berwanger, Otávio; Azevedo, Luciano César Pontes de; Lopes, Renato Delascio; Avezum, Álvaro; Kawano-Dourado, Leticia; Damiani, Lucas Petri; Rojas, Salomón Soriano Ordinola; Oliveira, Cleyton Zanardo de; Andrade, Luis Eduardo Coelho; Sandes, Alex Freire; Pintão, Maria Carolina; Castro Júnior, Claudio Galvão de; Scheinberg, Phillip; Veiga, Viviane Cordeiro.
Rev. bras. ter. intensiva ; 32(3): 337-347, jul.-set. 2020. tab, graf
Artigo em Inglês, Português | LILACS | ID: biblio-1138506

Documentos relacionados

  1. Rationale and design of the "Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled" trial (TOCIBRAS).
  2. Why tocilizumab could be an effective treatment for severe COVID-19?
  3. Effective treatment of severe COVID-19 patients with tocilizumab.
  4. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
  5. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.
  6. [Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT)].
  7. Tocilizumab in COVID-19 interstitial pneumonia.
  8. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
  9. Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia.
  10. How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.